BlackRock Maintains Significant Stake in Crinetics Pharma
Ticker: CRNX · Form: SC 13G/A · Filed: Jan 25, 2024 · CIK: 1658247
| Field | Detail |
|---|---|
| Company | Crinetics Pharmaceuticals, Inc. (CRNX) |
| Form Type | SC 13G/A |
| Filed Date | Jan 25, 2024 |
| Risk Level | low |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, amendment, passive-investing
TL;DR
**BlackRock still holds Crinetics stock, signaling long-term confidence.**
AI Summary
BlackRock, Inc. filed an amended SC 13G/A on January 25, 2024, disclosing its ownership of Crinetics Pharmaceuticals, Inc. common stock as of December 31, 2023. This amendment (Amendment No. 3) indicates BlackRock continues to hold a significant, though passive, stake in Crinetics. This matters to investors because BlackRock is a major institutional investor, and their continued holding suggests confidence in Crinetics' long-term prospects, potentially signaling stability for the stock.
Why It Matters
BlackRock's continued, passive ownership in Crinetics Pharmaceuticals, Inc. signals institutional confidence, which can provide a sense of stability for current and prospective shareholders.
Risk Assessment
Risk Level: low — This filing indicates a passive, institutional holding by BlackRock, which generally reduces volatility risk rather than increasing it.
Analyst Insight
An investor should view BlackRock's continued passive holding as a sign of stability, but recognize it doesn't imply an immediate catalyst for price movement. It's a data point for long-term confidence rather than short-term trading.
Key Players & Entities
- BlackRock, Inc. (company) — the reporting person and institutional investor
- Crinetics Pharmaceuticals, Inc. (company) — the subject company whose stock is being reported
- December 31, 2023 (date) — the date of the event requiring the filing
- January 25, 2024 (date) — the filing date of the SC 13G/A amendment
FAQ
What type of filing is this document?
This document is an SC 13G/A, which is an amendment to a Schedule 13G filing, as indicated by 'FORM TYPE: SC 13G/A' and '(Amendment No: 3)' in the filing.
Who is the reporting person in this filing?
The reporting person is BlackRock, Inc., as stated under '(1)Names of reporting persons. BlackRock, Inc.' in the filing.
What is the name of the issuer whose securities are being reported?
The name of the issuer is Crinetics Pharmaceuticals, Inc., as specified under '(Name of Issuer) Crinetics Pharmaceuticals, Inc.' in the filing.
What was the date of the event that required this filing?
The date of the event which required this filing was December 31, 2023, as stated under '(Date of Event Which Requires Filing of this Statement) December 31, 2023'.
Under which rule was this Schedule 13G filed?
This Schedule was filed under Rule 13d-1(b), indicated by '[X] Rule 13d-1(b)' in the filing.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on January 25, 2024 regarding Crinetics Pharmaceuticals, Inc. (CRNX).